China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has announced a strategic partnership with compatriot firm CorrGene, a rare disease and cancer gene and cell therapy developer headquartered in Wuxi. The collaboration aims to deepen the companies’ involvement in the cell and gene therapy (CGT) field. No financial details of the partnership were disclosed.
Porton’s CDMO Service Platform
Founded in 2018, Porton has established itself as a leading CDMO with an end-to-end gene and cell therapy service platform. The platform covers a broad range of therapeutic areas, including plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy, and live bacterial therapy. This comprehensive service offering positions Porton to support the development and manufacturing of innovative therapies across multiple modalities.
CorrGene’s CRISPR 2.0 Technology
CorrGene, founded in 2022, operates out of China, Spain, and the US, and is known for its CRISPR 2.0 precision therapy gene editing technology platform. This advanced technology offers enhanced precision and efficiency in gene editing, making it a valuable asset in the development of gene and cell therapies for rare diseases and cancer.
Strategic Implications of the Partnership
The partnership between Suzhou Porton Biologics and CorrGene represents a significant step forward in the CGT field. By combining Porton’s extensive CDMO capabilities with CorrGene’s innovative CRISPR 2.0 technology, the companies aim to accelerate the development and commercialization of novel therapies. This collaboration is expected to enhance the treatment options available for patients with rare diseases and cancer, leveraging the strengths of both organizations to drive innovation and improve patient outcomes.-Fineline Info & Tech
